Lead Sponsor

University of California, Los Angeles

Collaborators

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

No

•taking prescribed BZs for at least 3 months prior to baseline and have a positive UDS for BZs at baseline
•currently experiencing significant distress or impairment due to their anxiety symptoms (i.e., score ≥ 6 on the OASIS during screening
•have been prescribed opioids for at least 3 months for pain management and have a positive UDS for prescribed opioids at baseline
•are between 18-85 years old
•are fluent in English
•have access to a digital device with internet access for telehealth
•are willing to reduce BZ use.

•pregnancy
•psychiatric symptoms requiring a higher level of care (i.e., severe suicidality, manic or psychotic symptoms not stabilized on medication)
•presence of any SUD other than tobacco use disorder, OUD (co-occurring with pain condition) or sedative/hypnotic use disorder)
•medical conditions that require ongoing treatment with benzodiazepines (e.g., certain seizure disorders)
•use of drugs other than BZs and opioids in the past 30 days (as indicated by UDS and self-report), with the exception of intermittent cannabis use (not meeting criteria for CUD) and use of alcohol above at-risk drinking cutoffs per US Dietary Guidelines
•marked cognitive impairment.

Related studies

NCT06066983 · Autism Spectrum Disorder, Anxiety Disorders

NCT06968026 · Recurrent Pregnancy Loss, Anxiety Disorders

NCT07174947 · Hepatobiliary Malignancy, Fluoxetine, and more

NCT07432945 · Anxiety, Anxiety Disorders

NCT06661460 · ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Specific Phobia, and more

Benzodiazepine Taper With Cognitive Behavioral Therapy in Patients Using Prescription Opioids